Sagimet Biosciences

🇺🇸United States
Ownership
-
Employees
10
Market Cap
$97.8M
Website
Introduction

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). ...

A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

First Posted Date
2023-04-28
Last Posted Date
2023-12-26
Lead Sponsor
Sagimet Biosciences Inc.
Target Recruit Count
48
Registration Number
NCT05835180
Locations
🇭🇺

Geza Lakner, Kistarcsa, Hungary

🇺🇸

Thomas C. Marbury, Orlando, Florida, United States

🇺🇸

Eric J. Lawitz, MD, San Antonio, Texas, United States

Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2022-12-20
Last Posted Date
2022-12-28
Lead Sponsor
Sagimet Biosciences Inc.
Target Recruit Count
8
Registration Number
NCT05657834
Locations
🇺🇸

Celerion Inc., Lincoln, Nebraska, United States

Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)

First Posted Date
2021-05-28
Last Posted Date
2023-12-26
Lead Sponsor
Sagimet Biosciences Inc.
Target Recruit Count
162
Registration Number
NCT04906421
Locations
🇺🇸

Om Research LLC, Lancaster, California, United States

🇺🇸

Panax Clinical Research, Miami Lakes, Florida, United States

🇺🇸

Care Access, Ogden, Utah, United States

and more 101 locations

Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

First Posted Date
2019-05-06
Last Posted Date
2024-12-19
Lead Sponsor
Sagimet Biosciences Inc.
Target Recruit Count
142
Registration Number
NCT03938246
Locations
🇨🇳

Shanghai Tongren Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, Shanghai, China

🇺🇸

ProSciento, Chula Vista, California, United States

🇺🇸

Catalina Research Institute, Montclair, California, United States

and more 20 locations

A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors

Phase 1
Completed
Conditions
Interventions
First Posted Date
2014-08-22
Last Posted Date
2017-08-14
Lead Sponsor
Sagimet Biosciences Inc.
Target Recruit Count
180
Registration Number
NCT02223247
© Copyright 2024. All Rights Reserved by MedPath